Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial.

Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, Campbell KA, Choti MA

Annals of surgery1 Sept 2000Cited by 373 (Europe PMC)

PMID10973392DOI10.1097/00000658-200009000-00014PepBankPUB-10973392

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialSafety outcome
After pancreaticoduodenectomy, fistula rates were 11% with octreotide and 9% with saline.
In plain wordsAfter pancreatic surgery, fistula rates were 11% with octreotide and 9% with saline.
Peptide
Octreotide
Outcome
IncreasePancreatic fistula
Study
n = 211
Comparator
Saline control
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Studied dose
250 microg every 8 hours · subcutaneous · 7 daysAs given in this study (human).
Measurements
Pancreatic fistula rate
11%
octreotide arm
Pancreatic fistula rate
9%
saline control arm
Source sentences
Summary
The pancreatic fistula rates were 9% in the control group and 11% in the octreotide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients who gave consent were randomized to saline control versus octreotide 250 microg subcutaneously every 8 hours for 7 days, to start 1 to 2 hours before surgery.
Summary · context
Two hundred eleven patients underwent pancreaticoduodenectomy with pancreatic-enteric anastomosis, received appropriate saline/octreotide doses, and were available for endpoint analysis.
Report a problemFND-1097339201
02HumanRandomized controlled trialSafety outcome
After pancreaticoduodenectomy, overall complications occurred in 40% with octreotide versus 34% with saline.
In plain wordsAfter pancreatic surgery, complications occurred in 40% with octreotide versus 34% with saline.
Peptide
Octreotide
Outcome
IncreaseOverall complications
Study
n = 211
Comparator
Saline control
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
250 microg every 8 hours · subcutaneous · 7 daysAs given in this study (human).
Measurements
Overall complication rate
40%
octreotide arm
Overall complication rate
34%
saline control arm
Source sentences
Summary
The overall complication rates were 34% in the control group and 40% in the octreotide group; the in-hospital death rates were 0% versus 1%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients who gave consent were randomized to saline control versus octreotide 250 microg subcutaneously every 8 hours for 7 days, to start 1 to 2 hours before surgery.
Summary · context
Two hundred eleven patients underwent pancreaticoduodenectomy with pancreatic-enteric anastomosis, received appropriate saline/octreotide doses, and were available for endpoint analysis.
Report a problemFND-1097339202
03HumanRandomized controlled trialSafety outcome
After pancreaticoduodenectomy, in-hospital mortality was 1% with octreotide versus 0% with saline.
In plain wordsAfter pancreatic surgery, hospital deaths occurred in 1% with octreotide versus 0% with saline.
Peptide
Octreotide
Outcome
IncreaseIn-hospital death
Study
n = 211
Comparator
Saline control
Analysis
Primary
Outcome group
Mortality · Whole body
Studied dose
250 microg every 8 hours · subcutaneous · 7 daysAs given in this study (human).
Measurements
In-hospital death rate
1%
octreotide arm
In-hospital death rate
0%
saline control arm
Source sentences
Summary
The overall complication rates were 34% in the control group and 40% in the octreotide group; the in-hospital death rates were 0% versus 1%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients who gave consent were randomized to saline control versus octreotide 250 microg subcutaneously every 8 hours for 7 days, to start 1 to 2 hours before surgery.
Summary · context
Two hundred eleven patients underwent pancreaticoduodenectomy with pancreatic-enteric anastomosis, received appropriate saline/octreotide doses, and were available for endpoint analysis.
Report a problemFND-1097339203
04HumanRandomized controlled trialEfficacy outcome
After pancreaticoduodenectomy, median hospital stay was 9 days with either octreotide or saline.
In plain wordsAfter pancreatic surgery, median hospital stay was 9 days with either octreotide or saline.
Peptide
Octreotide
Outcome
No significant changePostoperative hospital stay
Study
n = 211
Comparator
Saline control
Analysis
Primary
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
250 microg every 8 hours · subcutaneous · 7 daysAs given in this study (human).
Measurements
Median postoperative length of hospital stay
9 days
octreotide arm
Median postoperative length of hospital stay
9 days
saline control arm
Source sentences
Summary
The median postoperative length of hospital stay was 9 days in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients who gave consent were randomized to saline control versus octreotide 250 microg subcutaneously every 8 hours for 7 days, to start 1 to 2 hours before surgery.
Summary · context
Two hundred eleven patients underwent pancreaticoduodenectomy with pancreatic-enteric anastomosis, received appropriate saline/octreotide doses, and were available for endpoint analysis.
Report a problemFND-1097339204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02474914

Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy

Mansoura Universityn = 104May 2014 to Apr 2017

Periampullary Carcinoma Resectable

Trial page ClinicalTrials.govUpdated 22 Aug 2017

CompletedPhase 4NCT01301222

Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas

PVS Memorial Hospitaln = 110Sept 2010 to Feb 2015

Pancreatic Fistula

Trial page ClinicalTrials.govUpdated 24 Feb 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.